EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy
Kang J, Ko A, Kil S, Mallen-St Clair J, Shin D, Wang M, Srivatsan E. EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. Biochimica Et Biophysica Acta (BBA) - Reviews On Cancer 2022, 1878: 188827. PMID: 36309124, DOI: 10.1016/j.bbcan.2022.188827.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorReceptor tyrosine kinasesEGFR mAbsNeck cancerEGFR monoclonal antibody cetuximabEra of immunotherapyTreatment of HNCMonoclonal antibody cetuximabTyrosine kinase inhibitorsEGFR variant IIIGrowth factor receptorMetastatic HNCEGFR resistanceImmune cellsClinical trialsOnly FDAAntibody cetuximabGrowth factor ligandsSmall molecule inhibitorsVariant IIIMTOR pathwayCombinatorial treatmentEGFR overexpressionTumor microenvironmentImmunotherapyUse of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case–Control Studies of COVID-19 Vaccine Effectiveness
Hitchings MDT, Lewnard JA, Dean NE, Ko AI, Ranzani OT, Andrews JR, Cummings DAT. Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case–Control Studies of COVID-19 Vaccine Effectiveness. Epidemiology 2022, 33: 450-456. PMID: 35384900, PMCID: PMC9148635, DOI: 10.1097/ede.0000000000001484.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccine effectivenessVaccine effectivenessNegative control exposureObservational studyControl exposurePhase III trialsTest-negative studiesTest-negative casesVaccine effectiveness estimatesCOVID-19 vaccineDemonstration of efficacyCOVID-19 riskIII trialsUnvaccinated individualsClinical trialsControl studyStudy designEffectiveness estimatesCareful study designUnmeasured confoundingSelection biasTrialsConfoundingExposureIndividuals